|
1
|
Zuo TT, Zheng RS, Zhang SW, Zeng HM and
Chen WQ: Incidence and mortality of liver cancer in China in 2011.
Chin J Cancer. 34:508–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altekruse SF, Henley SJ, Cucinelli JE and
McGlynn KA: Changing hepatocellular carcinoma incidence and liver
cancer mortality rates in the United States. Am J Gastroenterol.
109:542–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kulik L and El-Serag HB: Epidemiology and
management of hepatocellular carcinoma. Gastroenterology.
156:477–491.e1. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hiotis SP, Rahbari NN, Villanueva GA,
Klegar E, Luan W, Wang Q and Yee HT: Hepatitis B vs hepatitis C
infection on viral hepatitis-associated hepatocellular carcinoma.
BMC Gastroenterol. 12:642012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu T, Seto WK, Zhu RX, Lai CL and Yuen MF:
Prevention of hepatocellular carcinoma in chronic viral hepatitis B
and C infection. World J Gastroenterol. 19:8887–8894. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saran U, Humar B, Kolly P and Dufour JF:
Hepatocellular carcinoma and lifestyles. J Hepatol. 64:203–214.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tarocchi M, Polvani S, Marroncini G and
Galli A: Molecular mechanism of hepatitis B virus-induced
hepatocarcinogenesis. World J Gastroenterol. 20:11630–11640. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marra M, Sordelli IM, Lombardi A, Lamberti
M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R,
Accardo M, et al: Molecular targets and oxidative stress biomarkers
in hepatocellular carcinoma: An overview. J Transl Med. 9:1712011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sawey ET, Chanrion M, Cai C, Wu G, Zhang
J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, et al:
Identification of a therapeutic strategy targeting amplified FGF19
in liver cancer by oncogenomic screening. Cancer Cell. 19:347–358.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan W, Li W, Zhao J, Huang Z, Zhao J, Chen
S, Wang C, Xue Y, Huang F, Fang Q, et al: lncRNA-PDPK2P promotes
hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3
pathway. Mol Oncol. 13:2246–2258. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li CH and Chen Y: Targeting long
non-coding RNAs in cancers: Progress and prospects. Int J Biochem
Cell Biol. 45:1895–1910. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang P, Yang X, Zhao L, Liu D, Liu J and
Ding Y: A novel long non-coding RNA TONSL-AS1 regulates progression
of gastric cancer via activating TONSL. Exp Cell Res.
382:1114532019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du
Y, Luo X, Zheng F, Liu R, Zhang H and Ma D: miRNA-135a promotes
breast cancer cell migration and invasion by targeting HOXA10. BMC
Cancer. 12:1112012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park S, Choi S, Cho YA, Sinn DH, Kim JM,
Park CK and Ha SY: Evaluation of the American joint committee on
cancer (AJCC) 8th edition staging system for hepatocellular
carcinoma in 1,008 patients with curative resection. Cancer Res
Treat. 52:1145–1152. 2020.PubMed/NCBI
|
|
17
|
Lang N, Wang C, Zhao J, Shi F, Wu T and
Cao H: Long non-coding RNA BCYRN1 promotes glycolysis and tumor
progression by regulating the miR-149/PKM2 axis in non-small-cell
lung cancer. Mol Med Rep. 21:1509–1516. 2020.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bertuccio P, Turati F, Carioli G,
Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends
and predictions in hepatocellular carcinoma mortality. J Hepatol.
67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mao XP, Zhang LS, Huang B, Zhou SY, Liao
J, Chen LW, Qiu SP and Chen JX: Mir-135a enhances cellular
proliferation through post-transcriptionally regulating PHLPP2 and
FOXO1 in human bladder cancer. J Transl Med. 13:862015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu S, Guo W, Shi J, Li N, Yu X, Xue J, Fu
X, Chu K, Lu C, Zhao J, et al: MicroRNA-135a contributes to the
development of portal vein tumor thrombus by promoting metastasis
in hepatocellular carcinoma. J Hepatol. 56:389–396. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zeng YB, Liang XH, Zhang GX, Jiang N,
Zhang T, Huang JY, Zhang L and Zeng XC: miRNA-135a promotes
hepatocellular carcinoma cell migration and invasion by targeting
forkhead box O1. Cancer Cell Int. 16:632016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie Y, Li F, Li Z and Shi Z: miR-135a
suppresses migration of gastric cancer cells by targeting
TRAF5-mediated NF-κB activation. Onco Targets Ther. 12:975–984.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang C, Zheng X, Ye K, Sun Y, Lu Y, Fan Q
and Ge H: miR-135a inhibits the invasion and migration of
esophageal cancer stem cells through the hedgehog signaling pathway
by targeting Smo. Mol Ther Nucleic Acids. 19:841–852. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang J, Yang J, Zhang H, Liao Y, Xu D and
Ma S: Effects of miR-135a-5p and miR-141 on proliferation, invasion
and apoptosis of colorectal cancer SW620 cells. Oncol Lett.
20:914–920. 2020. View Article : Google Scholar : PubMed/NCBI
|
